COVERAGE HUB
$SNDX
2 articles in last 30 days
LAST 30 DAYS
2 articles
AVG GRADE
NEUTRAL
score: 0.00
SENTIMENT
BULLISH
TOTAL VIEWS
0
1-DAY GRADE TIMELINE
2026-06-11
TODAY
RECENT COVERAGE · 2 ARTICLES
Syndax Pharmaceuticals: The Duration Expansion Story Is Being Underpriced (NASDAQ:SNDX)
Syndax Pharmaceuticals (SNDX) has transitioned into a validated multi-product oncology platform, with both Revuforj and Niktimvo...
Syndax Showcases Revuforj® (revumenib) Clinical Activity in Multiple Acute Leukemia Subtypes and Settings at EHA 2026
Syndax Pharmaceuticals (SNDX) presented clinical data for revumenib (Revuforj®) at the European Hematology Association 2026 conference,...